2026-05-08T21:04:56Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/199032024-09-27T08:26:09Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Ríos-Tamayo, Rafael author Lecumberri, Ramón author Cibeira, María Teresa author González-Calle, Verónica author Alonso, Rafael author Domingo-González, Amalia author Landete, Elena author Encinas, Cristina author Iñigo, Belén author Blanchard, María-Jesús author Alejo, Elena author Krsnik, Isabel author Gómez-Bueno, Manuel author Garcia-Pavia, Pablo author Segovia-Cubero, Javier author Rosiñol, Laura author Lahuerta, Juan-José author Martínez-López, Joaquín author Bladé, Joan author 2024-04-26 Systemic AL amyloidosis is a challenging disease for which many patients are considered frail in daily clinical practice. However, no study has so far addressed frailty and its impact on the outcome of these patients. We built a simple score to predict mortality based on three frailty-associated variables: age, ECOG performance status (<2 vs. ≥2) and NT-proBNP (<8500 vs. ≥8500 ng/L). Four-hundred and sixteen consecutive newly diagnosed patients diagnosed at ten sites from the Spanish Myeloma Group were eligible for the study. The score was developed in a derivation cohort from a referral center, and it was externally validated in a multicenter cohort. Multivariate analysis showed that the three variables were independent predictors of survival. The score was able to discriminate four groups of patients in terms of overall survival and early mortality in both cohorts. Comorbidity was also analyzed with the Charlson comorbidity index, but it did not reach statistical significance in the model. A nomogram was created to easily estimate the mortality risk of each patient at each time point. This score is a simple, robust, and efficient approach to dynamically assess frailty-dependent mortality both at diagnosis and throughout follow-up. The optimal treatment for frail AL amyloidosis patients remains to be determined but we suggest that the estimation of frailty-associated risk could complement current staging systems, adding value in clinical decision-making in this complex scenario. Cancers (Basel). 2024 Apr 26;16(9):1689. 10.3390/cancers16091689 2072-6694 Cancers 38730641 http://hdl.handle.net/20.500.12105/19903 A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.